SAN DIEGO, Dec. 3, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of molecular
offerings designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that clinical data supporting the use of its
Target Selector™ CTC platform as an aid in the monitoring and
treatment of breast cancer will be presented in a poster session at
the 2019 San Antonio Breast Cancer Symposium® (SABCS). The
Symposium is being held December
10-14, at the Henry B. Gonzalez Convention Center in
Austin, Texas. Information about
the SABCS can be found at www.sabcs.org/2019-SABCS.
Poster and session details:
Title: Clinical Data in Over 1,500 Patients Across
All Stages of Breast Cancer with Target Selector Circulating Tumor
Cell Technology
Authors: Veena M. Singh M.D.
et al.
Session Title: Poster Session 4
Session Date and Time: Friday,
December 13, 7:00 a.m. - 9:00 a.m.
(EDT)
"Our CTC-based liquid biopsy testing offers physicians the
ability to assess metastatic disease burden and informative
biomarkers to aid clinical decision making in patients with
breast cancer," said Veena
Singh, MD, Senior Vice President and Senior Medical Director
at Biocept. "Additionally, our liquid biopsy testing affords the
ability to contemporaneously monitor an evolving tumor mutation
landscape in a cost-effective and minimally invasive
manner for disease progression, recurrence, emergence of
resistance mechanisms, and identification of potentially
actionable therapeutic targets."
"We are very pleased to showcase this large data set at SABCS
demonstrating the ability of our Target Selector™ assays to
help physicians better understand treatment options for their
patients with breast cancer," said Biocept's President and CEO
Michael Nall. "Our liquid biopsy
platform provides the unique ability to utilize our proprietary CTC
testing to capture and count cancer cells as well as interrogate
them for specific biomarkers, thereby personalizing a patient's
treatment. Because we use a simple blood sample, our assays can be
used to monitor patients and assess treatment response throughout
the continuum of care. We look forward to presenting additional
clinical data for our novel assays at major medical conferences in
the future."
About the 2019 San Antonio Breast Cancer Symposium®
SABCS's mission is to provide state-of-the-art information on
breast cancer research. From a one-day regional conference, the
Symposium has grown to a five-day program attended by a broad
international audience of academic and private researchers and
physicians from over 90 countries. SABCS aims to achieve a balance
of clinical, translational, and basic research, providing a forum
for interaction, communication, and education for a broad spectrum
of researchers, health professionals, and those with a special
interest in breast cancer.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including,
without limitation, statements as to our ability to improve the
management, diagnosis and treatment of cancer, and the ability of
our tests to provide clinically actionable information to
oncologist and their patients, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at http://www.sec.gov/.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocepts-liquid-biopsy-ctc-testing-for-breast-cancer-to-be-featured-in-poster-presentation-at-the-2019-san-antonio-breast-cancer-symposium-300967937.html
SOURCE Biocept, Inc.